Treatment of patients with pulmonary fibrosis. Chronic respiratory failure
Conditions
Interventions
Intervention 1: Intervention group: 30 patients are in the intervention group, for whom the injection of mesenchymal stem cells from the pulp of deciduous teeth will be performed. Clinical examination
Sponsors
Kerman University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Age 18 to 75 years High-resolution computed tomography (HRCT) scan compatible with the presumptive diagnosis of common interstitial pneumonia Bronchoalveolar lavage has ruled out other diagnoses. At least 3 months have passed since the onset of the disease and bibasilar inspiratory crackles are present. In addition, the following abnormalities are present: dyspnea score of at least 2 on a scale of 0 (minimum) to 10 (maximum), FVC > 50% and DLco > 35% of the predicted value. Patients who wish to sign an informed consent form Patients treated with N-acetylcysteine ??or pirfenidone should discontinue the drug 6 weeks prior to treatment.
Exclusion criteria
Exclusion criteria: Patients with severe IPF, i.e. those with FVC <50 and DLCO <35% predicted normal limit Patients with lung cancer or other malignancies Patients with a history of uncontrolled underlying diseases such as heart, kidney, or liver disease. Patients with significant neurological abnormalities, including stroke and myasthenia gravis Patients treated with anticoagulant drugs or in severe weight loss Patients with active infection. Patients whose condition cannot be monitored regularly, including those with serious psychiatric disorders. Patients who are unwilling to sign an informed consent form
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lung diffusing capacity. Timepoint: Every 12 weeks up to a year after injection. Method of measurement: Measurement with the device.;Total lung volume. Timepoint: Every 12 weeks up to a year after injection. Method of measurement: Measurement with the device.;Measuring people's overall health. Timepoint: Every 12 weeks up to a year after injection. Method of measurement: 6-minute walk test.;Ratio of arterial oxygen pressure to inspiratory oxygen pressure. Timepoint: Every 12 weeks up to a year after injection. Method of measurement: Arterial blood gas test.;Determining the condition of the lungs. Timepoint: Every 12 weeks up to a year after injection. Method of measurement: Chest X-ray. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAlireza Farsinejad
Kerman University of Medical Sciences
Outcome results
None listed